Cashew Leads Tree Nut-Induced Anaphylaxis in Children
In over 1000 cases of physician-diagnosed episodes of tree nut-induced anaphylaxis (TIA), tree nuts accounted for 23% of all reported episodes of food-induced anaphylaxis, establishing their role as major food allergens. Cashew emerged as the most frequent elicitor of TIA in children, whereas hazelnut was the leading cause of TIA in adults.
METHODOLOGY:
Researchers collected data from the European Anaphylaxis Registry between 2007 and April 2024, involving 142 specialized allergy centers across Brazil and 13 countries in Europe.
A total of 1389 cases of TIA were documented, with the specific elicitor confirmed in 1083 cases: 845 children (median age, 4 years; 61% boys) and 238 adults (median age, 38 years; 60% women).
Phenotype-specific features characterized by age distributions, symptoms, and the severity of the reaction and the presence of potential cofactors and comorbidities were identified, and time trends and regional patterns of TIA were analyzed.
TAKEAWAY:
Among children, cashew elicited 40% of TIA cases, followed by hazelnut (25%) and walnut (17%). In adults, hazelnut (44%) was the leading cause, followed by walnut (20%) and almond (15%).
Children reacted to smaller amounts than adults, with 76% of children and 20% of adults reacting to less than a tablespoon of cashew ( P = .015). Similar patterns were observed for hazelnut, walnut, and other tree nuts.
= .015). Similar patterns were observed for hazelnut, walnut, and other tree nuts. Previous reactions to the allergen that caused TIA were reported in 25% of children and 33% of adults, yet only 23% of children and 21% of adults were aware of their tree nut allergy beforehand.
Only 13% of children and 3% of adults received adrenaline during lay treatment compared with 42% of children and 39% of adults who received it during professional treatment.
IN PRACTICE:
'Primary prevention to avoid tree nut allergy in general is necessary, followed by the education of patients about the potential role of cofactors, which were present in up to 50% of affected adults and which might have increased the reaction severity from otherwise mild to anaphylactic reactions,' the authors of this study wrote.
SOURCE:
Margitta Worm, with Charité – Universitätsmedizin Berlin, Berlin, Germany, was the corresponding author of the study, which was published online on June 13 in Allergy .
LIMITATIONS:
This study was limited by the under-representation of adults, missing data on fatal cases, and the prevalence of TIA in general. Additionally, the data derived from specialized allergy centers might have led to a bias toward more severe or initial reactions.
DISCLOSURES:
This work was supported by NORA e.V., Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, the Swiss National Science Foundation, the Swiss Cancer Research Foundation, and the EU-H2020-MSCA-COFUND EURIdoc program. Some authors reported providing consultation and speaker/advisor services or receiving grants, research funding, honoraria or consultation fees, or payment for presentations from various pharmaceutical and other companies. One author reported holding stocks in EssilorLuxottica.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
EMA Recommends Rezdiffra for MASH Liver Fibrosis
The European Medicines Agency (EMA) has recommended conditional marketing authorization for Rezdiffra (resmetirom) for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. MASH was formerly known as nonalcoholic fatty liver disease (NASH). There are currently no authorized treatments for MASH in the EU, making Rezdiffra a potential first. MASH is a serious liver disease that occurs when fat accumulates in the liver, causing inflammation. Left untreated, it can lead to cirrhosis and cancer. Symptoms may only present in more advanced stages of the condition, at which point they may include discomfort or pain in the upper right abdomen, muscle weakness or loss, and swelling in the abdomen or legs. Estimates suggest that up to 5% of people in Europe have MASH and that around 25% have metabolic dysfunction‐associated steatotic liver disease (MASLD), the condition that precedes MASH. MASLD was previously known as nonalcoholic fatty liver disease (NAFLD). The active substance of Rezdiffra is resmetirom, which is a partial agonist of the thyroid hormone receptor-beta. It works by promoting lipophagy and hepatic fatty acid beta-oxidation to reduce liver fat, inflammation, and liver fibrosis. The EMA's decision comes after interim results from a pivotal, ongoing phase 3 trial including 966 adults with biopsy-confirmed MASH with varying stages of fibrosis. Patients were randomly assigned treatment on a 1:1:1 ratio to receive once-daily resmetirom at 80 mg or 100 mg, or a placebo. The primary endpoints were MASH resolution at week 52 with no worsening of fibrosis, and a reduction in fibrosis by at least one stage alongside no worsening of NAFLD activity score. MASH resolution included a reduction in the NAFLD activity score by ≥ 2 points. Scores range from 0 to 8; higher scores indicate more severe disease. After 12 months, 30% of patients in the 100 mg resmetirom group and 26% of those in the 80 mg group achieved MASH resolution with no worsening fibrosis compared with 10% in the placebo group. Meanwhile, 26% of patients in the 100 mg resmetirom group and 24% of patients in the 80 mg group experienced fibrosis improvement by at least one stage with no worsening of NAFLD activity score compared with 14% in the placebo group. The most frequent side effects were diarrhea, nausea, itching, and pruritus. Diarrhea and nausea were more frequent among those taking resmetirom than those taking the placebo. The rate of serious adverse events was similar across all groups and ranged from 10.9% to 12.7%. Rezdiffra will be available as 60 mg, 80 mg, and 100 mg film-coated tablets. It should be taken alongside diet and exercise. The opinion adopted by the EMA will now go to the European Commission to await a decision on EU-wide marketing authorization. In the meantime, the EMA has required Rezdiffra's applicant to complete both the pivotal and another ongoing trial to provide further data regarding the drug's efficacy. This conditional approval comes as the EMA perceives that the benefits to patients from immediate availability outweigh the risk inherent in incomplete data. Detailed recommendations for using Rezdiffra will be described in the summary of product characteristics, which will be published on the EMA website in all official European Union languages.
Medscape
2 hours ago
- Medscape
EMA Reviews Alcohol Dependency Drug After French Concerns
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced it will review the use of medicines containing sodium oxybate, a drug used in narcolepsy, in people with alcohol dependency. The review comes at the request of the French Medicines Agency and has been initiated under Article 31 of Directive 2001/83/EC. This procedure is used to address concerns over the safety or benefit-risk balance of a medicine or a class of medicines; to resolve disagreements between member states on issues related to the authorization of medicines; or to give an opinion on an issue of Europe-wide interest so that the agency can make a recommendation for a harmonized position across the EU. The European Commission, any member state, or the company that markets the medicine can initiate a referral. In a referral, the European Medicines Agency (EMA) is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union. It involves the matter being referred to the Pharmacovigilance Risk Assessment Committee (PRAC) after due notice to the EMA, all member states, and the European Commission. Narcolepsy Indication Sodium oxybate (Xyrem) is the sodium salt of gamma-hydroxybutyric acid. As an oral solution (500 mg/mL), it is indicated for the treatment of narcolepsy with cataplexy in adult patients, adolescents, and children from the age of 7 years. The drug is a central nervous system depressant believed to act by attaching to brain cell receptor molecules to promote delta (slow) brain waves and nighttime sleep. When taken at bedtime, Xyrem increases sleep depth and length, reducing the number of sleeping periods during the day and improving symptoms of narcolepsy. Because of the drug's potential for abuse, it can only be obtained with a special prescription, and treatment should be initiated and maintained under the guidance of a doctor with experience in treating sleep disorders. Doctors are advised to check for a history of or susceptibility to drug abuse before treatment, and to monitor for misuse and abuse during treatment. Approved for Alcohol Abuse in Austria and Italy The drug has also been suggested to reduce pain and improve function in fibromyalgia, but the EMA said the data were insufficient to support its use for this in the European population. However, sodium oxybate is also approved in Italy and in Austria, under the name Alcover, to treat alcohol dependence and alcohol withdrawal syndrome. It is this use that the review will examine. The EMA has confirmed the positive benefit-risk profile of the treatment as prescribed in Italy and Austria. France, however, despite having a high prevalence of alcohol problems, has resisted its use for this purpose. Trials have suggested that sodium oxybate can rapidly alleviate symptoms of alcohol withdrawal syndrome and was at least as effective as diazepam and clomethiazole. It can also be used in the maintenance of abstinence in alcohol-dependent patients, in whom it is reportedly as effective as naltrexone or disulfiram. Because existing approved medications are only modestly effective, there is a pressing need for effective treatments with an alternative mode of action, particularly in patients with very high consumption levels. Sodium oxybate also has a favorable safety profile. However, studies in alcohol use disorder have been limited and further investigations have been recommended.
Associated Press
3 hours ago
- Associated Press
How to stay cool in the heat wave hitting parts of the US --even without air conditioning
The first big heat wave of 2025 has arrived, coinciding with the official start of summer . More than 40 million people in the U.S. were under heat alerts Friday, according to the National Weather Service. Temperatures in the Midwest are expected to crest well into the 90s Fahrenheit (30s Celsius) this weekend. Triple-digit highs could pop up in New York, Philadelphia, Washington and Denver. The peak will likely hit the East Coast early next week. Meanwhile, British health officials are also issuing heat warnings for the U.K . Climate change has been exacerbating heat waves, and the problem isn't going away any time soon. An increasingly hot planet — due largely to burning fossil fuels such as coal, oil and natural gas — means already hot regions are getting worse . Heat doesn't just mean canceled events . It also poses a health risk, especially for children, older people and those with certain health conditions. So here are some tips to stay safe. When does heat become dangerous? The answer depends on more than the temperature. The most detailed measurement is called the wet bulb globe temperature (WBGT), which includes temperature, humidity, cloud cover and wind. The heat index, which measures temperature and humidity, is less descriptive but easier to find on weather apps. Both explain why a shaded soccer field on a 90 degree F day (32 degree C) in arid Phoenix may be less risky than an exposed park on an 80 degree F (27 degree C) day in soupy Little Rock. Just based on heat index, NOAA has a chart that calculates how dangerous prolonged exposure can be. For example, a day where temperatures reach 96 degree F (36 degrees C) and 45% humidity would fall into the 'danger' category for prolonged exposure or strenuous activity. The WBGT threshold isn't exact, but recent research suggests that even some young, healthy people can't endure hours of exposure to high heat and humidity. How to cool down Overnight lows can be a particularly dangerous part of a heat wave, said Ashley Ward, director of the Heat Policy Innovation Hub at Duke University. 'Your body needs a reprieve,' she said. 'You don't get that overnight, we start the next day at a deficit.' Heat can worsen labor productivity and lead to more visits to the emergency room. 'When we have overnight temperatures that don't drop below 75 degrees' F (24 degrees C), she said, 'You start to see some pretty extraordinary outcomes with respect to heat illness and heat stroke, and even mortality.' Ward's answer: Find air conditioning. That might be at home, but she said census data overcounts how many people have access. If you can't afford to cool the whole house, Ward said, create a 'cool corner' and sleep there, so your body is prepared to tackle the next day. Evaporative or 'swamp' coolers can help in dry heat, but they increase humidity and can make it more difficult to cool down. In humid places, just use a fan. If you don't have air conditioning, find public places that do, including movie theaters, malls and libraries. Some communities set up cooling centers. Depending on where you live, the Low-Income Home Energy Assistance Program can help you buy a window air conditioning unit, according to the National Council on Aging . Some local nonprofits and civic organizations can also help you access one if cost is a burden. Know your rights if you work outside Knowing what workplace protections you have is important. But there are no federal heat rules to protect workers in the United States. Some states have them, including Washington, Oregon, California, Nevada, Colorado, Minnesota and Maryland, according to the National Resources Defense Council. Other states don't have any. If your state has work rules, try to learn them — though there are still challenges to ensuring regulations are actually enforced, said Bharat Venkat, director of the University of California, Los Angeles Heat Lab. He notes that sometimes shaded areas are too far for workers to take breaks without losing wages, or that management can make it impossible for workers to advocate for themselves. 'Most workers don't actually have control over their time or control over where they work,' he said. Within those constraints, finding ways to stay hydrated and lower your body temperature are paramount. You can do this by drinking lots of fluids, wetting clothing or putting cold water or a cold rag on your hands, feet, armpits and neck. A portable handheld fan or a cooling vest can also help. If you're exercising, avoid the hottest times of day and bring more water than you think you need. Knowing heat illness symptoms Heat illness symptoms can vary by person, Venkat said. Medications or underlying conditions can also make it harder to regulate body temperature or notice you're getting too hot. Early trouble signs include heavy sweating, muscle cramps and headache. That's when you stop what you're doing and cool yourself off — for example, by splashing yourself with cold water or finding an air conditioned space. As heat exhaustion sets in, new symptoms arrive, including faster heart rate and dizziness. Next comes heat stroke, which can include confusion, slurred words and fainting. Ward said that's when to call 911. 'Don't be embarrassed to call 911 or go to urgent care when you think you might have overdone it in the heat,' he said. ___ Walling reported from Chicago. Wells reported from Cleveland. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at .
